Targeting Microglial Immunoproteasome: A Novel Approach in Neuroinflammatory-Related Disorders

Area of Science:

• Neuroscience
• Immunology
• Cell Biology

Background:

• Aging is associated with increased damaged protein accumulation and altered proteasome activity, specifically decreased chymotrypsin-like proteasome (c20S) and increased immunoproteasome (i20S).
• Chronic neuroinflammation, involving microglia activation, is implicated in various neurological disorders, including Alzheimer's and Parkinson's disease.
• Increased i20S activity may promote neuroinflammation by presenting self-antigens, triggering autoimmune responses and exacerbating neurodegeneration.

Purpose of the Study:

• To review the mechanisms of neuroinflammation and microglia activation.
• To explore the role of immunoproteasome (i20S) in neuroinflammation and neurodegenerative diseases.
• To evaluate the therapeutic potential of i20S inhibitors for neuroinflammatory disorders.

Main Methods:

• Literature review of studies on aging, protein aggregation, neuroinflammation, microglia, and proteasomes.
• Analysis of the role of i20S in immune responses within the central nervous system.
• Examination of preclinical and clinical data on i20S inhibitors in neurological disease models.

Main Results:

• Chronic neuroinflammation is linked to decreased c20S and increased i20S activity.
• Elevated i20S activity contributes to autoimmune responses and neurodegeneration.
• Disrupted i20S function can prolong inflammation and lead to cell death.

Conclusions:

• The immunoproteasome (i20S) plays a critical role in neuroinflammation and neurodegeneration.
• Targeting i20S with inhibitors presents a promising therapeutic strategy for managing neuroinflammatory diseases.
• Further research into i20S modulation could lead to novel treatments for conditions like Alzheimer's and Parkinson's disease.